$1.02
10.53%
Nasdaq, Nov 17, 04:00 pm EST.
ISIN
US31189P1021
Symbol
FATE

Fate Therapeutics, Inc. Stock price

$1.02
-0.84 45.16% 1M
-0.71 41.04% 6M
+0.04 3.81% YTD
+0.05 4.83% 1Y
-1.41 58.02% 3Y
-52.46 98.09% 5Y
-1.69 62.36% 10Y
-5.60 84.59% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.12 10.53%
ISIN
US31189P1021
Symbol
FATE
Industry

Is Fate Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$124.0m
Enterprise Value
$-17.9m
Net debt
positive
Cash
$153.8m
Shares outstanding
116.7m
Valuation
P/E
negative
P/S | estimate
19.1 | 25.0
EV/Sales | estimate
negative | negative
EV/FCF | ex SBC
0.2 | 0.1
P/B
0.8
Financial Health
Equity Ratio
65.0%
Return on Equity
-65.8%
ROCE
-58.7%
ROIC
-
Debt/Equity
0.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$17.8m | 274.9%
SBC as % of FCF
-
SBC Growth 1Y
-49.6%
Share Count Growth 1Y
1.8%
Shareholder Yield
-1.8%
Financials
Revenue | estimate
$6.5m | $5.0m
EBITDA
$-121.6m
EBIT
$-133.6m
Net Income
$-126.0m
Free Cash Flow | ex SBC
$-105.7m | $-123.5m
Growth
Revenue | estimate
-23.4% | -25.5%
EBITDA
31.0%
EBIT
30.6%
Net Income
26.5%
Free Cash Flow
11.0%
Margin
Gross
-
EBITDA
-1,873.4%
EBIT
-2,058.1%
Net
-1,941.1%
Free Cash Flow | ex SBC
-1,627.8% | -1,902.5%
More
EPS
$-1.1
FCF per Share
$-0.9
Short interest
9.3%
Employees
161
Rev per Employee
$40.0k

Fate Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Fate Therapeutics, Inc. forecast:

11x Buy
61%
7x Hold
39%

Analyst Opinions

18 Analysts have issued a Fate Therapeutics, Inc. forecast:

Buy
61%
Hold
39%

Financial data from Fate Therapeutics, Inc.

Jun '26
+/-
%
6.49 6.49
23% 23%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
35% 35%
612%
- Research and Development Expense 100 100
20% 20%
1,546%
-122 -122
31% 31%
-1,874%
- Depreciation and Amortization 12 12
25% 25%
185%
EBIT (Operating Income) EBIT -134 -134
31% 31%
-2,058%
Net Profit -126 -126
27% 27%
-1,941%

In millions USD.

Don't miss a Thing! We will send you all news about Fate Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fate Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
●
8 days ago
Updated safety data of 36 patients treated with FT819 across three regimens and four autoimmune disease indications with no dose-limiting toxicities continues to be favorable 100% (3 of 3) of extrarenal lupus patients treated with FT819 without the use of conditioning chemotherapy experienced measurable responses with two patients achieving the Definition of Remission in Systemic Lupus Erythema...
Neutral
GlobeNewsWire
●
13 days ago
Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN
Neutral
GlobeNewsWire
●
15 days ago
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 2, 2026, the Company granted (i) non-qualif...
More Fate Therapeutics, Inc. News

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Dr. Valamehr
Employees 161
Founded 2007
Website fatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today